1. Berndt MC, Kabral A, Grimsley P, et al. An acquired Bernard-Soulier—like defect associated with juvenile myeloproliferative syndrome. Br J Haematol. 1988; 68:97-101.
2. Nittyvuopio R, Juvonen E, Kekomaki R, et al. The predictive value of megakaryocytic and erythroid colony formation and platelet function tests on the risk of thromboembolic and bleeding complications in essential thrombocythaemia. Eur J Haematol. 2004; 72:245-251.
3. Goerttler PL, Marz E, Johansson PL, et al. Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels. Haematologica. 2005; 90:851-853.
4. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006; 91:169-175.
5. Harrison CN, Campbell PJ, Wheatley K, et al. Hydroxyurea compared to anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353:33-45.